The bio tech stocks have on average risen by 188% this year and have a median upside potential of 150%.
Related Posts
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the […]
Asia-Pacific stocks trade mixed as investors parse through a slew of economic data
The Reserve Bank of New Zealand cut rates by 50-basis-points to 3.75% in line with Reuters’ estimates.
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face competition from cheaper generics.